Upstream Bio (UPB) Interest & Investment Income (2023 - 2026)
Upstream Bio's quarterly Interest & Investment Income came in at $3.1 million in Q1 2026, down 35.61% year-on-year from $4.7 million in Q1 2025, and down 16.42% quarter-over-quarter from $3.7 million in Q4 2025.
Upstream Bio has reported Interest & Investment Income for 4 years, with the latest figure at $3.1 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 35.61% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (down 2.28% YoY), and the FY2025 full-year result was $16.9 million, up 39.68% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $3.1 million, down from $3.7 million in the prior quarter.
- The five-year high for Interest & Investment Income was $5.1 million in Q4 2024, with the low at $1.3 million in Q1 2024.
- Average Interest & Investment Income over 4 years is $3.2 million, with a median of $3.1 million recorded in 2026.
- Year-over-year, Interest & Investment Income surged 274.64% in 2025 and plunged 35.61% in 2026.
- Tracing UPB's Interest & Investment Income over 4 years: stood at $1.5 million in 2023, then surged by 234.17% to $5.1 million in 2024, then fell by 28.01% to $3.7 million in 2025, then retreated by 16.42% to $3.1 million in 2026.
- The last three Interest & Investment Income figures came in at $3.1 million (Q1 2026), $3.7 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.05 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 4.11 Mn |
| Jun 30, 2025 | 4.43 Mn |
| Mar 31, 2025 | 4.74 Mn |
| Dec 31, 2024 | 5.08 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 2.88 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.53 Mn |